Full history for every metric is available with a Kvantra account
ObsEva S.A. (OBSV)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 20 | 20 |
| Operating profit | $m | -16 | -35 | |||||
| Net profit | $m | -67 | -77 | -109 | -83 | -58 | -30 | -30 |
| EPS reported | $ | -0.32 | -0.37 | |||||
| Operating cashflow per share | $ | -0.25 | -0.25 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.25 | -0.25 | |||||
| Free cash flow | $m | -23 | -23 | |||||
| Net debt | $m | -5 | -6 | |||||
| Book value equity | $m | 8 | 8 | |||||
| Book value per share | $ | 0.09 | 0.09 | |||||
| Number of shares | m | 92.08 | 92.08 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.57 | 1.30 | |||||
| P/S LTM | x | 0.68 | 0.56 | |||||
| P/FCF LTM | x | -0.58 | -0.48 | |||||
| EV/EBITDA LTM | x | -0.40 | 0.39 | |||||
| EV/Sales LTM | x | 0.41 | 0.27 | |||||
| Earnings Yield LTM | % | -223.78% | -318.75% | |||||
| FCF Yield | % | -173.33% | -210.48% | |||||
| Quality | ||||||||
| ROE | % | -352.22% | -146.39% | |||||
| ROIC | % | -126.58% | -126.58% | |||||
| Operating margin | % | -79.83% | -79.83% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -117.85% | -117.85% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -7.65 | -7.65 | |||||
| Net Debt/EBITDA | x | 0.27 | 0.27 | |||||
| EBIT/Net interest | x | -1.70 | -1.70 | |||||
| Net debt/market cap | % | -40.42% | -51.23% | |||||
| Net debt/Equity | x | -0.64 | -0.66 | |||||
| Gross debt/equity | x | 0.36 | 0.36 | |||||
Company overview
ObsEva S.A. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for conditions affecting women's reproductive health and pregnancy. A key part of their development pipeline is Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, currently in Phase III clinical trials. This drug aims to mitigate pain associated with endometriosis and reduce heavy menstrual bleeding stemming from uterine fibroids in pre-menopausal women. Additionally, the company is progressing Ebopiprant, a selective oral prostaglandin F2a (PGF2a) receptor antagonist, through Phase II trials as a once-daily therapy for preterm labor occurring between 24 and 34 weeks of gestation. Their portfolio also includes Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical development, designed to enhance clinical pregnancy and live birth outcomes for women undergoing in vitro fertilization. Founded in 2012, ObsEva S.A. operates from its headquarters in Geneva, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ObsEva S.A. (OBSV)
ObsEva S.A. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for conditions affecting women's reproductive health and pregnancy. A key part of their development pipeline is Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, currently in Phase III clinical trials. This drug aims to mitigate pain associated with endometriosis and reduce heavy menstrual bleeding stemming from uterine fibroids in pre-menopausal women. Additionally, the company is progressing Ebopiprant, a selective oral prostaglandin F2a (PGF2a) receptor antagonist, through Phase II trials as a once-daily therapy for preterm labor occurring between 24 and 34 weeks of gestation. Their portfolio also includes Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical development, designed to enhance clinical pregnancy and live birth outcomes for women undergoing in vitro fertilization. Founded in 2012, ObsEva S.A. operates from its headquarters in Geneva, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free